Literature DB >> 21709096

In vitro potency of various polymyxin B components.

Vincent H Tam, Henry Cao, Kimberly R Ledesma, Ming Hu.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21709096      PMCID： PMC3165278          DOI： 10.1128/AAC.00119-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  9 in total

1.  Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40.

Authors:  Karen Lolans; Thomas W Rice; L Silvia Munoz-Price; John P Quinn
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Comment on: Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma.

Authors:  Vincent H Tam; Jingguo Hou; Andrea L Kwa; Randall A Prince
Journal:  J Antimicrob Chemother       Date:  2008-11-19       Impact factor: 5.790

3.  Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection.

Authors:  Jooyun Lee; Gopi Patel; Shirish Huprikar; David P Calfee; Stephen G Jenkins
Journal:  J Clin Microbiol       Date:  2009-03-04       Impact factor: 5.948

4.  Variability of polymyxin B major components in commercial formulations.

Authors:  Jie He; Kimberly R Ledesma; Wai-Ying Lam; Deborah A Figueroa; Tze-Peng Lim; Diana S-L Chow; Vincent H Tam
Journal:  Int J Antimicrob Agents       Date:  2009-12-31       Impact factor: 5.283

Review 5.  Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms.

Authors:  Zhe Yuan; Vincent H Tam
Journal:  Expert Opin Investig Drugs       Date:  2008-05       Impact factor: 6.206

6.  Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B.

Authors:  David Landman; Simona Bratu; Maqsood Alam; John Quale
Journal:  J Antimicrob Chemother       Date:  2005-05-09       Impact factor: 5.790

7.  Isolation and structural characterization of polymyxin B components.

Authors:  J A Orwa; C Govaerts; R Busson; E Roets; A Van Schepdael; J Hoogmartens
Journal:  J Chromatogr A       Date:  2001-04-06       Impact factor: 4.759

8.  Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa.

Authors:  Vincent H Tam; Kai-Tai Chang; Kamilia Abdelraouf; Cristina G Brioso; Magdalene Ameka; Laurie A McCaskey; Jaye S Weston; Juan-Pablo Caeiro; Kevin W Garey
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

9.  Contribution of OmpK36 to carbapenem susceptibility in KPC-producing Klebsiella pneumoniae.

Authors:  David Landman; Simona Bratu; John Quale
Journal:  J Med Microbiol       Date:  2009-06-25       Impact factor: 2.472
  9 in total
  12 in total

Review 1.  Antimicrobial Susceptibility Testing for Polymyxins: Challenges, Issues, and Recommendations.

Authors:  Fereshteh Ezadi; Abdollah Ardebili; Reza Mirnejad
Journal:  J Clin Microbiol       Date:  2019-03-28       Impact factor: 5.948

Review 2.  Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.

Authors:  Laurent Poirel; Aurélie Jayol; Patrice Nordmann
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

3.  Comparative Pharmacokinetic Profiling of Different Polymyxin B Components.

Authors:  Pooja Manchandani; Yanina Dubrovskaya; Song Gao; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

4.  Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model.

Authors:  Jie He; Kamilia Abdelraouf; Kimberly R Ledesma; Diana S-L Chow; Vincent H Tam
Journal:  Int J Antimicrob Agents       Date:  2013-08-22       Impact factor: 5.283

5.  Comparing the Population Pharmacokinetics of and Acute Kidney Injury Due to Polymyxin B in Chinese Patients with or without Renal Insufficiency.

Authors:  Peile Wang; Qiwen Zhang; Zhenfeng Zhu; Hui Pei; Min Feng; Tongwen Sun; Jing Yang; Xiaojian Zhang
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

6.  Microbiological Assessment of Polymyxin B Components Tested Alone and in Combination.

Authors:  Zahra Kassamali; Randall A Prince; Larry H Danziger; John C Rotschafer; Paul R Rhomberg; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

7.  Direct modifications of the cyclic peptide Polymyxin B leading to analogues with enhanced in vitro antibacterial activity.

Authors:  Pamela Brown; Omar Abdulle; Steven Boakes; Esther Duperchy; Stephen Moss; Mona Simonovic; Steven Stanway; Antoinette Wilson; Michael J Dawson
Journal:  Bioorg Med Chem Lett       Date:  2020-03-30       Impact factor: 2.823

8.  Pharmacokinetics and renal disposition of polymyxin B in an animal model.

Authors:  Kamilia Abdelraouf; Jie He; Kimberly R Ledesma; Ming Hu; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

9.  Antimicrobial Activity and Toxicity of the Major Lipopeptide Components of Polymyxin B and Colistin: Last-line Antibiotics against Multidrug-Resistant Gram-negative Bacteria.

Authors:  Kade D Roberts; Mohammad A K Azad; Jiping Wang; Andrew S Horne; Philip E Thompson; Roger L Nation; Tony Velkov; Jian Li
Journal:  ACS Infect Dis       Date:  2015-09-04       Impact factor: 5.084

10.  A validated ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies.

Authors:  Jie He; Song Gao; Ming Hu; Diana S-L Chow; Vincent H Tam
Journal:  J Antimicrob Chemother       Date:  2013-01-22       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.